Clinical Uses of Blended Genome–Exome Sequencing

In precision medicine, success relies on understanding not only which variants a patient carries, but how those variants interact with broader biological pathways, risk factors, and disease mechanisms. This is especially important when combatting multi-factorial conditions such as pancreatitis, complex liver disease, and metabolic dysfunction; conditions shaped by a mix of rare coding variants and cumulative polygenic influences.

The narrow view offered by many genomic tests can be a headache for clinicians: Targeted panels focus on a limited set of variants. Whole-exome sequencing (WES) reveals coding changes but overlooks regulatory and non-coding regions. Whole-genome sequencing (WGS) provides broader insight but can be resource-intensive and difficult to interpret at scale. As a result, important contributors, from structural variants to polygenic influences and disease-specific biomarkers, may remain disconnected from the clinical picture.

Blended genome-exome (BGE) sequencing helps bridge this gap. By pairing low-pass genome coverage with deep exome sequencing, the approach delivers both breadth and depth in a single assay. When supported by disease-aware interpretation that incorporates polygenic risk, phenotypic context, and biomarker data, it can be a game-changing tool for differential diagnosis, risk assessment, and patient management.

In this blog, we share how a clinically-validated blended genome-exome assay, developed in partnership between Eremid Genomic Services and Ariel Precision Medicine, is already driving new insight in the clinic. From liver and biliary disorders to pancreatitis and pancreatic cancer, we show how this integrated approach is opening doors across metabolic and oncologic disease areas and beyond.

A clinically validated blended genome-exome sequencing assay

Blended genome-exome sequencing brings together two complementary data types from a single sample. It pairs low-pass WGS with high-depth WES, creating a unified dataset that captures both genome-wide patterns and rare, high-impact coding variants. This enables simultaneous evaluation of monogenic drivers, modifier genes, and polygenic risk factors – valuable for investigating complex, multi-system diseases¹.

The low-pass WGS layer also supports detection of broader structural patterns, such as structural variants, copy-number variation and other large-scale genomic alterations where resolution permits.

Figure 1: Blended genome-exome sequencing combines high-coverage whole exome sequencing (green) with low-pass whole genome sequencing (blue) from a single sample.

Learn more about Eremid’s approach to blended genome-exome sequencing

Recognizing the need for a sequencing approach that truly serves clinical and translational applications, Eremid has partnered with Ariel Precision Medicine to create a novel BGE sequencing assay optimized for precision medicine. The assay builds on Eremid’s deep genomics expertise and Ariel’s proprietary bioinformatics algorithm and disease knowledge. It is fully validated and performed in a CLIA- and CAP-accredited laboratory, ensuring the analytical performance, QC, and reproducibility required for clinical use.

What sets this assay apart is how seamlessly the sequencing data connects to Ariel’s precision medicine platform and disease-aware analytic framework. Rare pathogenic and predisposing variants are interpreted alongside polygenic risk scores derived from genome-wide signals, and these findings are integrated with relevant phenotypes, biomarkers, and clinical context.

This all combines to enable the assay’s outputs to flow directly into models that support diagnosis, risk stratification, and patient management. The result is a cost-friendly, clinic-ready solution that pairs high-quality sequencing with meaningful, context-rich interpretation.

The BGE assay’s design supports multiple real-world applications, including:

• Early-stage clinical research, where integrated genomic insight can accelerate understanding of disease drivers
• Clinical trials, where genomic stratification can improve cohort selection, identify likely responders, and support biomarker development
• Laboratory-developed tests (LDTs) for diagnostics, risk assessment, and ongoing patient management

Together, these capabilities open the door to a wide spectrum of clinical and translational applications: from refining diagnostic workups and anticipating disease progression to informing treatment decisions and supporting genomic enrichment strategies in clinical trials.

BGE assay application example: liver and biliary disease

Liver and biliary diseases frequently present with non-specific or overlapping features, such as abnormal liver injury tests, steatosis, cholestasis, pruritus, jaundice, or ambiguous imaging findings². Many of these conditions are genetically driven, yet traditional genomic tests often focus narrowly on a handful of monogenic drivers, missing the combination of pathogenic variants, predisposing variants, and polygenic risk factors that shape liver disease. This creates a diagnostic gap where clinicians may struggle to distinguish between metabolic, cholestatic, autoimmune, hereditary, or drug-induced etiologies.

The Eremid-Ariel blended genome-exome clinical assay directly addresses this diagnostic challenge by capturing the full spectrum of genetic causes of liver and biliary disease. The high-depth WES component enables detection of well-characterized monogenic drivers across key hepatobiliary pathways, while the low-pass WGS layer supports genome-wide polygenic risk assessment. Together, these layers provide a comprehensive view of both rare and cumulative genetic risk (Table 1).

Table 1: Integrated Genomic Coverage for Liver and Biliary Disease

This dual-layer coverage is essential because many patients don’t present with a single pathogenic variant; instead, they exhibit combinatorial genetic risk that modifies severity, progression, and comorbidities.

Ariel’s disease-aware analytics integrate these findings with phenotype, biomarker results, and clinician-provided history, transforming the genomic signals into a clinically actionable report.

Outcomes from the Eremid-Ariel BGE assay report:

• Primary disease drivers aligned with the presenting indication
• Modifier genes and comorbidity risks, including fibrosis progression, cirrhosis, or malignancy risk
• Differential diagnostic considerations, distinguishing metabolic, cholestatic, autoimmune, hereditary, or drug-induced mechanisms
• Risk stratification insights, including factors that may accelerate disease progression or influence treatment decisions
• Clinical actionability, such as when specialist referral is warranted and management-relevant insights (e.g., risk for extrahepatic cardiometabolic or pancreatobiliary complications)

By unifying monogenic and polygenic data with biomarker and phenotype interpretation, the BGE assay provides a much clearer diagnostic pathway for patients with complex presentations. Isolated genetic findings are replaced with a complete integrated picture that supports early diagnosis, prognosis, and personalized patient management.

BGE assay application example: pancreatitis and pancreatic cancer

 Pancreatitis is one of the clearest examples of a condition where genetic risk is distributed across multiple pathways rather than concentrated in a single causal variant. Acute or chronic presentations may arise from ductal dysfunction, enzyme activation defects, impaired fluid secretion, metabolic abnormalities, or underlying immune and inflammatory processes³.

Many of these pathways intersect with those involved in diabetes, dyslipidemia, fibrosis, NAFLD/NASH, intestinal disorders, and cancer susceptibility, creating a highly interconnected disease network. Traditional genomic testing struggles to capture this level of complexity.

The blended genome-exome clinical assay bridges this gap by combining rare variant detection with genome-wide signals that influence disease initiation, severity, and progression. The deep exome layer supports confident detection of pathogenic variants across genes relevant to ductal function, enzyme regulation, and metabolic pathways, while the low-pass WGS layer contributes broader polygenic risk information. Together, these layers provide an integrated genomic view of pancreatitis (Table 2).

Table 2: Integrated Genomic Coverage for Liver and Biliary Disease

This integrated genomic view becomes especially powerful when considering the downstream risk of pancreatic cancer. Many of the pathways that drive chronic pancreatitis overlap significantly with those implicated in pancreatic cancer development, fibrosis progression, and metabolic comorbidities⁴. Assessing monogenic susceptibility alongside polygenic risk helps clarify which patients could be at heightened risk of progression.

Ariel’s analytic framework brings these signals together with phenotype and biomarker data to produce actionable insight.

Outcomes from the Eremid-Ariel BGE assay report:

• Primary disease drivers, including variant patterns linked to ductal, enzyme-regulation, metabolic, or CFTR-associated mechanisms
• Modifier and comorbidity risks that may influence inflammation, fibrosis progression, metabolic burden, or cancer susceptibility
• Differential diagnostic clarity, helping distinguish hereditary pancreatitis, metabolic drivers, autoimmune features, or secondary causes
• Risk stratification indicators, including variant combinations or polygenic patterns associated with faster progression or recurrence
• Clinical actionability, such as identifying patients who may benefit from closer surveillance, targeted interventions, or pharmacogenomic-guided therapy in research or clinical settings

Compared to traditional genomic testing, BGE sequencing provides a more complete genomic picture of pancreatitis and its wider disease landscape in a single test—helping clinicians and researchers anticipate progression, differentiate overlapping etiologies, and design more tailored management and research strategies.

Extending integrated genomics across therapeutic areas

The combined strengths of blended genome-exome sequencing and disease-aware analytics make the approach highly applicable and adaptable to a wide range of complex diseases. Many conditions share overlapping genetic, metabolic, and inflammatory pathways, and as such, the ability to evaluate multiple risk factors within a single workflow has substantial clinical and translational relevance. This integrated approach could be particularly valuable in conditions such as:

• NAFLD/NASH, where metabolic and inflammatory drivers influence progression
• Dyslipidemia and hypertriglyceridemia, shaped by both rare variants and polygenic burden
• Obesity and metabolic syndrome, where cumulative genome-wide risk affects severity and comorbidities
• Fibrotic disorders, where genetic and environmental modifiers intersect
• Cancer susceptibility, where shared pathways help identify patients at higher risk of progression

Another key advantage of the BGE approach is its cost efficiency compared with traditional WGS, while providing greater genomic breadth than exome-only strategies. This balance of depth and coverage supports clinical-scale use across translational programs, clinical studies, and longitudinal care without prohibitive sequencing costs.

Toward a new era of integrated precision medicine

The integration of blended genome-exome sequencing into a validated clinical assay signals an important shift in how we approach complex diseases. Instead of navigating fragmented genetic clues, clinicians and researchers can access a unified view of risk, mechanism, and progression; opening the door to earlier insight and more tailored interventions.

As this approach extends across hepatology, pancreatitis, metabolic disorders, and oncology, it offers a glimpse of a future where our understanding of a patient’s genomic landscape is not only comprehensive, but genuinely actionable. With scalable implementation and growing clinical relevance, the BGE sequencing assay marks an exciting step toward more precise, predictive, and proactive medicine.

Ready to bring integrated genomics into your research or clinical program?

Learn how our blended genome-exome platform can support your next study or therapeutic initiative.

Contact Us

References 

1. DeFelice, M. et al. Blended Genome Exome (BGE) as a Cost Efficient Alternative to Deep Whole Genomes or Arrays. bioRxiv https://doi.org/10.1101/2024.04.03.587209 (2024) doi:10.1101/2024.04.03.587209.
2. Gan, C. et al. Liver diseases: epidemiology, causes, trends and predictions. Signal Transduction and Targeted Therapy 2025 10:1 10, 33- (2025).
3. Weiss, F. U., Laemmerhirt, F. & Lerch, M. M. Acute Pancreatitis: Genetic Risk and Clinical Implications. J. Clin. Med. 10, 190 (2021).
4. Kim, H. S. et al. Incidence and risk of pancreatic cancer in patients with chronic pancreatitis: defining the optimal subgroup for surveillance. Scientific Reports 2023 13:1 13, 106- (2023).